StockNews.com Begins Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS)

Equities research analysts at StockNews.com initiated coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report issued on Wednesday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

A number of other research analysts also recently weighed in on the stock. Oppenheimer upgraded shares of Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price target on the stock in a report on Monday, September 23rd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $4.00 target price on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. EF Hutton Acquisition Co. I upgraded shares of Marinus Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 30th. LADENBURG THALM/SH SH downgraded shares of Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday, August 14th. Finally, HC Wainwright reiterated a “neutral” rating and issued a $2.00 target price on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. Nine equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Marinus Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $4.79.

Marinus Pharmaceuticals Trading Down 7.9 %

Marinus Pharmaceuticals stock opened at $0.28 on Wednesday. The company has a market capitalization of $15.48 million, a P/E ratio of -0.11 and a beta of 1.25. The firm’s fifty day simple moving average is $0.87 and its 200-day simple moving average is $1.21. Marinus Pharmaceuticals has a 1-year low of $0.26 and a 1-year high of $11.26.

Institutional Trading of Marinus Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Hussman Strategic Advisors Inc. grew its position in Marinus Pharmaceuticals by 14.3% in the 2nd quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 10,500 shares during the last quarter. AQR Capital Management LLC boosted its position in shares of Marinus Pharmaceuticals by 70.3% during the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 12,934 shares in the last quarter. Point72 DIFC Ltd acquired a new stake in shares of Marinus Pharmaceuticals during the 2nd quarter valued at about $28,000. SG Americas Securities LLC acquired a new stake in shares of Marinus Pharmaceuticals during the 2nd quarter valued at about $34,000. Finally, Values First Advisors Inc. boosted its position in shares of Marinus Pharmaceuticals by 501.8% during the 2nd quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock valued at $73,000 after acquiring an additional 52,257 shares in the last quarter. 98.80% of the stock is currently owned by institutional investors and hedge funds.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.